News & Updates

Remibrutinib improves sleep, daily activities in patients with CSU

28 Mar 2025 by

Treatment with remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, improved sleep and daily activities in patients with chronic spontaneous urticaria (CSU), according to two phase III REMIX-1 and -2 studies presented at AAD 2025.

Remibrutinib improves sleep, daily activities in patients with CSU

28 Mar 2025

Sacubitril-valsartan a boon to hypertension patients with ESKD on dialysis

27 Mar 2025

Treatment with sacubitril-valsartan (SV) demonstrates good tolerability and may provide some benefits to hypertension patients with end-stage kidney disease (ESKD) who are undergoing dialysis, as shown by the results of a recent meta-analysis.

Sacubitril-valsartan a boon to hypertension patients with ESKD on dialysis

27 Mar 2025

Apremilast boasts long-term improvement in PPP

27 Mar 2025 by

Patients with palmoplantar pustulosis (PPP) treated with apremilast show improvements at week 16, with continued treatment resulting in maintained or further improvement at week 52, according to a study presented at AAD 2025. No new safety concerns have been observed.

Apremilast boasts long-term improvement in PPP

27 Mar 2025

Donepezil does little to improve post–COVID-19 fatigue, psychological symptoms

27 Mar 2025

Treatment with the acetylcholinesterase inhibitor donepezil hydrochloride falls short of improving post–COVID-19 conditions such as fatigue and psychological symptoms, as shown in a study from Japan.

Donepezil does little to improve post–COVID-19 fatigue, psychological symptoms

27 Mar 2025

Diclofenac no better than indomethacin for preventing post-ECRP pancreatitis

26 Mar 2025

For patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), prophylactic administration of rectal diclofenac does not appear to significantly reduce the incidence of pancreatitis after the procedure when compared with rectal indomethacin, according to a study from China.

Diclofenac no better than indomethacin for preventing post-ECRP pancreatitis

26 Mar 2025

Neoadjuvant chemoimmunotherapy beneficial in locally advanced ESCC

26 Mar 2025

In the treatment of locally advanced esophageal squamous cell carcinoma (ESCC), neoadjuvant chemoimmunotherapy may prolong overall and disease-free survival compared with neoadjuvant chemoradiotherapy, according to a study from China.

Neoadjuvant chemoimmunotherapy beneficial in locally advanced ESCC

26 Mar 2025

Baricitinib tied to hair regrowth in adolescents with severe AA

26 Mar 2025 by

Once-daily treatment with baricitinib resulted in clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes among adolescent patients with severe alopecia areata (AA), according to the BRAVE-AA-PEDS trial presented at AAD 2025.

Baricitinib tied to hair regrowth in adolescents with severe AA

26 Mar 2025

Repeated LSD treatment for ADHD symptoms only as good as placebo

25 Mar 2025

Repeated administration of low-dose lysergic acid diethylamide (LSD) in an outpatient setting is not necessarily better than placebo at reducing symptoms of attention-deficit/hyperactivity disorder (ADHD), according to the results of a phase IIA trial.

Repeated LSD treatment for ADHD symptoms only as good as placebo

25 Mar 2025

DOR/ISL noninferior to comparator ARTs in two phase III trials

25 Mar 2025 by

In adults with virologically suppressed HIV-1* infection, switching to a two-drug regimen of doravirine 100 mg and islatravir 0.25 mg (DOR/ISL) was noninferior to continuing bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or other baseline antiretroviral therapy (bART) regimens in maintaining viral suppression at 48 weeks, according to two phase III trials presented at CROI 2025.

DOR/ISL noninferior to comparator ARTs in two phase III trials

25 Mar 2025

SZC lowers hyperkalemia risk in HF patients on spironolactone

24 Mar 2025 by

The use of sodium zirconium cyclosilicate (SZC) among patients with heart failure (HF) and reduced ejection fraction (HFrEF) and hyperkalemia has significantly improved the proportion of those with normokalemia while on optimal spironolactone dose, a study has shown.

SZC lowers hyperkalemia risk in HF patients on spironolactone

24 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Remibrutinib improves sleep, daily activities in patients with CSU

Remibrutinib improves sleep, daily activities in patients with CSU

Sacubitril-valsartan a boon to hypertension patients with ESKD on dialysis

Sacubitril-valsartan a boon to hypertension patients with ESKD on dialysis

Apremilast boasts long-term improvement in PPP

Apremilast boasts long-term improvement in PPP

Donepezil does little to improve post–COVID-19 fatigue, psychological symptoms

Donepezil does little to improve post–COVID-19 fatigue, psychological symptoms

Diclofenac no better than indomethacin for preventing post-ECRP pancreatitis

Diclofenac no better than indomethacin for preventing post-ECRP pancreatitis

Neoadjuvant chemoimmunotherapy beneficial in locally advanced ESCC

Neoadjuvant chemoimmunotherapy beneficial in locally advanced ESCC

Baricitinib tied to hair regrowth in adolescents with severe AA

Baricitinib tied to hair regrowth in adolescents with severe AA

Repeated LSD treatment for ADHD symptoms only as good as placebo

Repeated LSD treatment for ADHD symptoms only as good as placebo

DOR/ISL noninferior to comparator ARTs in two phase III trials

DOR/ISL noninferior to comparator ARTs in two phase III trials

SZC lowers hyperkalemia risk in HF patients on spironolactone

SZC lowers hyperkalemia risk in HF patients on spironolactone